Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
-0.18%+4.58%+3.88%+31.79% 47.86B
-0.83%-0.67%+42.61%+34.77% 44.46B
-0.84%+5.34%+8.05%+91.52% 41.85B
-1.10%-6.89%+329.50%+535.80% 41.34B
-0.62%-0.06%+10.15%+46.02% 30.04B
-2.07%-0.54%+23.90%+154.30% 17.59B
-6.08%-6.94% - - 15.6B
-3.55%+3.65%+21.51%+38.83% 15.69B
-0.78%+11.24%-10.81% - 13.93B
Average -0.96%+2.66%+53.60%+133.29% 29.82B
Weighted average by Cap. -1.23%+1.88%+67.06%+141.32%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-